Aduro launching IPO
This article was originally published in Scrip
Executive Summary
Berkeley, California-based Aduro Biotech is planning to raise $86m through an initial public offering. The biotech, which is developing an immunotherapy for pancreatic cancer, will debut on Nasdaq under the symbol ADRO. Founded in 2000, Aduro initially filed its plans confidentially with the Securities and Exchange Commission (SEC) back in December 2014. No pricing terms were disclosed. Bank of America Merrill Lynch and Leerink Partners are the joint bookrunners on the deal. Aduro is developing CRS-207, a live attenuated strain of Listeria that Aduro has engineered to express human mesothelin, in combination with its GVAX Pancreas vaccine as a treatment for pancreatic cancer. It is currently in Phase IIb trials. A Phase II trial of the combination was stopped early in January 2014 on the strength of the data after a pre-planned interim analysis. Aduro has an ongoing partnership with Johnson & Johnson company Janssen Biotech for a number of products leveraging Aduro's technology.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.